V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund CVS Health Corp stake
total: 130
Dodge & Cox Stock Fund CVS trades
- Total transactions:
- 19
- New positions:
- 1
- Added:
- 11
- Reduced:
- 7
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Dodge & Cox Stock Fund holds 33,887,094 CVS Health Corp (CVS) shares with a market value of roughly $2.43B accounting for 2.12% of the overall portfolio. To date, the estimated cost basis is nearly $65.11 for "buy" trades and estimated average "sell" price is $74.36. Dodge & Cox Stock Fund first purchased CVS in 2019 Q3, initially acquiring about 12.04M shares. Since the initial investment in CVS Health Corp (CVS), Dodge & Cox Stock Fund has made 18 more transactions.
When did Dodge & Cox Stock Fund buy CVS Health Corp (CVS)?
Dodge & Cox Stock Fund first invested in CVS Health Corp (CVS) in 2019 Q3 at the reported quarter-end price of $63.07 per share.
What's the cost basis of Dodge & Cox Stock Fund's CVS stake?
The estimated cost basis for CVS Health Corp (CVS) stake is around $65.11 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $65.11
- Weighted AVG sell price:
- $74.36
Dodge & Cox Stock Fund's historical trades in CVS Health Corp
19 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.12%
|
33,887,094
|
$71.82
|
$2,433,771,091
|
-19.30% (-8,104,110)
|
-0.49%
|
|
2025 Q4
|
2.79%
|
41,991,204
|
$79.36
|
$3,332,421,949
|
-12.92% (-6,231,690)
|
-0.41%
|
|
2025 Q1
|
2.87%
|
48,222,894
|
$67.75
|
$3,267,101,068
|
+4.73% (+2,179,594)
|
+0.13%
|
|
2024 Q4
|
1.85%
|
46,043,300
|
$44.89
|
$2,066,883,737
|
+9.16% (+3,864,600)
|
+0.16%
|
|
2024 Q3
|
2.29%
|
42,178,700
|
$62.88
|
$2,652,196,656
|
+2.29% (+946,200)
|
+0.05%
|
|
2024 Q2
|
2.23%
|
41,232,500
|
$59.06
|
$2,435,191,450
|
+49.70% (+13,688,600)
|
+0.74%
|
|
2024 Q1
|
2.00%
|
27,543,900
|
$79.76
|
$2,196,901,464
|
+34.59% (+7,078,900)
|
+0.52%
|
|
2023 Q4
|
1.60%
|
20,465,000
|
$78.96
|
$1,615,916,400
|
+11.58% (+2,123,900)
|
+0.17%
|
|
2023 Q3
|
1.39%
|
18,341,100
|
$69.82
|
$1,280,575,602
|
+71.03% (+7,617,500)
|
+0.58%
|
|
2023 Q2
|
0.80%
|
10,723,600
|
$69.13
|
$741,322,468
|
+19.17% (+1,725,100)
|
+0.13%
|
|
2022 Q4
|
0.95%
|
$93.19
|
-2.19% (-201,200)
|
|||
|
2022 Q3
|
1.11%
|
$95.37
|
+0.19% (+17,000)
|
|||
|
2022 Q2
|
1.00%
|
$92.66
|
-1.32% (-122,700)
|
|||
|
2021 Q4
|
0.99%
|
$103.16
|
-4.43% (-431,000)
|
|||
|
2021 Q1
|
0.90%
|
$75.23
|
+4.95% (+459,600)
|
|||
|
2020 Q4
|
0.90%
|
$68.30
|
+3.31% (+297,600)
|
|||
|
2020 Q2
|
0.97%
|
$64.97
|
-25.14% (-3,015,400)
|
|||
|
2020 Q1
|
1.38%
|
$59.33
|
-0.39% (-46,900)
|
|||
|
2019 Q3
|
1.10%
|
$63.07
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.